Roivant director settles taxes with 2,905 shares

Roivant Sciences director James C. Momtazee had shares withheld to cover taxes on vested equity, with 106,905 common shares remaining directly held.

Rhea-AI Filing Summary

Roivant Sciences Ltd. (ROIV) director James C. Momtazee reported a Form 4 transaction involving the withholding of 2,905 Common Shares on September 10, 2026. The shares were withheld at $40.94 per share to satisfy tax withholding obligations upon vesting of equity granted under the company’s Non-Employee Director Compensation Plan, leaving him with 106,905 Common Shares held directly.

Insider Trade Summary

Tax Withholding: 2,905 shares

Tax Withholding 1 txn

Insider MOMTAZEE JAMES C

Role Director

Type	Security	Shares	Price	Value
Tax Withholding	Common Shares F1	2,905	$40.94	$119K

Holdings After Transaction: Common Shares — 106,905 shares (Direct)

Footnotes (1)

1. F1. Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

Key Figures

Shares withheld for tax: 2,905 shares Price per share: $40.94 per share Shares held after transaction: 106,905 shares

3 metrics

Shares withheld for tax 2,905 shares Common Shares withheld on September 10, 2026 to satisfy tax withholding obligations

Price per share $40.94 per share Valuation used for the 2,905 Common Shares withheld for taxes

Shares held after transaction 106,905 shares Common Shares directly held by James C. Momtazee after the withholding transaction

Key Terms

Non-Employee Director Compensation Plan, net settlement, tax withholding obligations

3 terms

Non-Employee Director Compensation Plan financial

"Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan"

net settlement financial

"Represents the "net settlement" by the Issuer of Common Shares previously granted"

tax withholding obligations financial

"in order to satisfy applicable tax withholding obligations in connection with the vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Roivant Sciences (ROIV) director James C. Momtazee report?

He reported a withholding of 2,905 Common Shares on September 10, 2026, used to pay tax withholding obligations related to the vesting and settlement of previously granted shares under Roivant’s Non-Employee Director Compensation Plan.

Was the Roivant (ROIV) Form 4 transaction a market sale or purchase?

No. The Form 4 describes a tax-withholding disposition, where 2,905 shares were delivered or withheld to satisfy tax obligations upon vesting, rather than an open-market sale or purchase of Roivant Sciences shares.

What price per share was used in the Roivant (ROIV) tax-withholding transaction?

The transaction used a price of $40.94 per Common Share for the 2,905 shares withheld to satisfy applicable tax withholding obligations tied to the vesting and settlement of Mr. Momtazee’s equity award.

How many Roivant (ROIV) shares does James C. Momtazee hold after this Form 4 event?

After the tax-withholding transaction, James C. Momtazee directly holds 106,905 Common Shares of Roivant Sciences Ltd., as reported in the Form 4 following the September 10, 2026 event.

Was the Roivant (ROIV) insider transaction under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not affirmatively marked, and the footnote describes a net settlement for tax withholding, not a discretionary trading plan transaction.

What is the source of the shares involved in the Roivant (ROIV) Form 4 tax withholding?

The 2,905 Common Shares represent a “net settlement” of shares previously granted to Mr. Momtazee under Roivant’s Non-Employee Director Compensation Plan, withheld to cover tax obligations at vesting and settlement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 06:26 PM EDT Accepted by SEC EDGAR 09/14/2026 - 06:25 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MOMTAZEE JAMES C

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON SW1H 0DB

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/10/2026		F		2,905(1)	D	$40.94	106,905	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

Remarks:

	By: /s/ Sam Kaplan, as Attorney-in-Fact for James C. Momtazee	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)